Biotech Values

[DewDiligence]

>Avastin seems to be all the street cares about<

That used to be true, but it’s not true anymore. Herceptin has had an amazing renaissance and Lucentis is the new kid on the block.

I predict there will be more discussion of AMD than of colorectal cancer on today’s CC. Analysts will push hard to get an AMD sales figure for Avastin, but DNA will not accommodate them.